Beste apotheek van Nederland

Baldwin D S. Sexual dysfunction associated with antidepressant
drugs. [Review] [96 refs]. Expert Opin Drug Saf 2004;3(5):457­
470.
Bancroft J. A history of sexual medicine in the United Kingdom.
Br J Sex Med 2005;2(4):569-574.
Basu A, Ryder R E. New treatment options for erectile
dysfunction in patients with diabetes mellitus. [Review] [88
refs]. Drugs 2004;64(23):2667-2688.
Beckman T J, Mynderse L A. Evaluation and medical
management of benign prostatic hyperplasia. Mayo Clin Proc
2005;80(10):1356-1362.
Beckman T J, bu-Lebdeh H S, Mynderse L A. Evaluation and
medical management of erectile dysfunction. [Review] [34 refs].
Mayo Clin Proc 2006;81(3):385-390.
Bella A J, Brock G B. Tadalafil in the treatment of erectile
dysfunction. [Review] [32 refs]. Curr Urol Rep 2003;4(6):472­
478.
Bella A J, Brock G B. Intracavernous pharmacotherapy for
erectile dysfunction. Endocrine 2004;23(2-3):149-155.
Bella A J, Brant W O, Brock G B. Contemporary intracavernous
pharmacotherapy for erectile dysfunction in the aging male.
Aging Health 2006;2(4):559-570.
Bellinghieri G, Santoro D, Lo Forti B et al. Erectile dysfunction
in uremic dialysis patients: Diagnostic evaluation in the
sildenafil era. Am J Kidney Dis 2001;38(4 SUPPL. 1):S115­
S117.
Bernstein A J, Peters K M. Expanding indications for
neuromodulation. Urol Clin North Am 2005;32(1):59-63.
Beutel M. Psychosomatic aspects in the diagnosis and treatment
of erectile dysfunction. [Review] [40 refs]. Andrologia 1999;31
Suppl 137-44.
Bhugra D, Crowe M. Physical treatments of erectile disorders.
Int Rev Psychiatry 1995;7(2):217-223.
Blanker Marco H, Verhagen Arianne P. Lipid-lowering drugs
and erectile dysfunction. [References]. Fam Pract
2002;19(5):567
Brant W O, Bella A J, Lue T F. Erectile and sexual dysfunction
in the aging diabetic male. Aging Health 2006;2(6):1025-1034.
Briganti A, Salonia A, Gallina A et al. Emerging oral drugs for
erectile dysfunction. [Review] [83 refs]. Expert Opinion on
Emerging Drugs 2004;9(1):179-189.
Brock G. Oral agents: First-line therapy for erectile dysfunction.
European Urology Supplements 2002;1(8):12-18.
Brock G B. Tadalafil: a new agent for erectile dysfunction.
[Review] [12 refs]. Can J Urol 2003;10Suppl-22.
Brock G B, Bochinski D. Modern pharmacotherapy
for erectile dysfunction: evolving concepts with
central and peripheral acting agents. [Review] [40
refs]. Curr Opin Urol 2001;11(6):625-630.
Brock G B, Lue T F. Drug-induced male sexual
dysfunction. An update. [Review] [88 refs]. Drug Saf
1993;8(6):414-426.
Broderick G A. Intracavernous pharmacotherapy:
Treatment for the aging erectile response. Urol Clin
North Am 1996;23(1):111-126.
Broderick G A. Changing practice patterns in erectile
dysfunction: a diagnostic algorithm for the new
millennium. [Review] [42 refs]. Adv Ren Replace
Ther 1999;6(4):314-326.
Broderick G A. Evidence based assessment of erectile
dysfunction. [Review] [62 refs]. Int J Impot Res
1998;10 Suppl 2S64-S73.
Brotons F B, Campos J C, Gonzalez-Correales R et al.
Core document on erectile dysfunction: Key aspects in
the care of a patient with erectile dysfunction. Int J
Impot Res 2004;16(SUPPL. 2):S26-S39.
Burnett A L. Phosphodiesterase 5 mechanisms and
therapeutic applications. Am J Cardiol 2005;96(12
SUPPL. 2):
Burns-Cox N, Gingell C. Medical treatment of erectile
dysfunction. [Review] [64 refs]. Postgrad Med J
1998;74(872):336-342.
Butler R N, Lewis M I, Hoffman E et al. Love and sex
after 60: how to evaluate and treat the impotent older
man. A roundtable discussion: Part 2.[see comment].
Geriatrics 1994;49(10):27-32.
Buvat J. Androgen therapy with
dehydroepiandrosterone. [Review] [89 refs]. World J
Urol 2003;21(5):346-355.
Carbone D J, Seftel A D. Erectile dysfunction.
Diagnosis and treatment in older men. [Review] [33
refs]. Geriatrics 2002;57(9):18-24.
Carrier S. Pharmacology of phosphodiesterase 5
inhibitors. [Review] [21 refs]. Can J Urol
2003;10Suppl-6.
Carrier S, Zvara P, Lue T F. Erectile dysfunction.
Endocrinology & Metabolism Clinics of North
America 1994;23(4):773-782.
Carson C C. Cardiac safety in clinical trials of
phosphodiesterase 5 inhibitors. Am J Cardiol
2005;96(12 SUPPL. 2):
D-38